APA

Mariz F. C., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M. R., Prabhu P. R., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Müller M. & Lehtinen M. (2020). Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. : NPJ vaccines.

Chicago

Mariz Filipe Colaço, Bender Noemi, Anantharaman Devasena, Basu Partha, Bhatla Neerja, Pillai Madhavan Radhakrisna, Prabhu Priya R, Sankaranarayanan Rengaswamy, Eriksson Tiina, Pawlita Michael, Prager Kristina, Sehr Peter, Waterboer Tim, Müller Martin and Lehtinen Matti. 2020. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. : NPJ vaccines.

Harvard

Mariz F. C., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M. R., Prabhu P. R., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Müller M. and Lehtinen M. (2020). Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. : NPJ vaccines.

MLA

Mariz Filipe Colaço, Bender Noemi, Anantharaman Devasena, Basu Partha, Bhatla Neerja, Pillai Madhavan Radhakrisna, Prabhu Priya R, Sankaranarayanan Rengaswamy, Eriksson Tiina, Pawlita Michael, Prager Kristina, Sehr Peter, Waterboer Tim, Müller Martin and Lehtinen Matti. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. : NPJ vaccines. 2020.